Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CURAFLEX/HEALTHINFUSION/MEDISYS MERGER WOULD CREATE THIRD LARGEST

Executive Summary

CURAFLEX/HEALTHINFUSION/MEDISYS MERGER WOULD CREATE THIRD LARGEST home infusion company based on revenues. The three companies signed a definitive merger agreement Dec. 1. Combined revenues of the three firms for the 12 months ended Sept. 30 were approximately $184.3 mil. The companies added that they would become the second largest direct provider of home infusion therapy services behind Caremark. Option Care, which operates through franchises, would remain second in terms of revenue. The new company will have "approximately 74 regional centers and seven disease-specific outpatient facilities located throughout the United States," the companies said. In addition, the companies maintain that the as-yet unnamed merged entity will be the leading home infusion service provider "in more than a dozen major metropolitan markets" including Miami, Tampa, Boston, Chicago, Phoenix, St. Louis, Dallas, Houston, Philadelphia, Kansas City, Omaha, southern California and Columbia, Md. Pursuant to the agreement, "all shares of common stock of Curaflex, HealthInfusion and Medisys issued and outstanding prior to the merger will be exchanged for shares of common stock of a newly-formed company." Curaflex shareholders will own 39.67% of the new company, HealthInfusion shareholders will own 37.67% and Medisys shareholders 22.67%, the companies said. Curaflex Chairman, President and CEO Charles Laverty will become the new company's chairman and CEO. HealthInfusion President and CEO Miles Gilman will take on the roles of vice chairman and president. Medisys CEO William Brummond will assume the exec VP post. Ontario, Calif.-based Curaflex calls itself "a national provider of comprehensive infusion therapy and related services to patients in the home and alternate site environments." The firm has 32 regional centers, four "satellite facilities" and seven "disease-specific outpatient centers focusing on the treatment of complex long-term diseases." Curaflex also operates a national prescription drug benefit program. Miami-based HealthInfusion "provides home infusion therapy services and supplies...in 26 states from 34 regional facilities." Minneapolis-based Medisys has home infusion centers in nine Western and Midwestern states. It also "provides comprehensive pharmacy services to long-term care and retirement communities" including "prescription dispensing, pharmaceutical consulting, I.V. therapy, enteral therapy and medical supplies," the firm said. Laverty described the deal as "a proactive response to the current healthcare environment, where operating efficiencies and the ability to withstand pricing pressures will be the key factors driving corporate profitability." The merger would cap a string of acquisitions by each of the three firms: the companies said they have acquired over 35 other firms in the past several years. The home infusion market has been growing as insurers and hospitals work to reduce hospital stays. The market could be further helped by passage of the Clinton Administration health reform plan, which mandates coverage of home care. The merger agreement is subject to shareholder approval at the three companies, Hart-Scott-Rodino antitrust clearance and acceptance of "pooling-of-interest" status. The agreement is expected to be completed by the end of the first quarter of 1994," the companies said. Each company has agreed to pay up to $3 mil. if it opts out of the deal in favor of another acquisition proposal.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS023703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel